This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KRON Kronos Bio (KRON) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Kronos Bio Stock (NASDAQ:KRON) Get Kronos Bio alerts:Sign Up Key Stats Today's Range$0.87▼$0.8850-Day Range$0.67▼$0.8952-Week Range$0.65▼$0.93Volume54,089 shsAverage Volume1.25 million shsMarket Capitalization$53.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California. Read More Receive KRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kronos Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KRON Stock News HeadlinesKronos Bio Insider Trading Activity | NASDAQ:KRON | BenzingaMay 14, 2026 | benzinga.com$1.8 billion fund is gobbling up Bay Area biotech 'zombies' for cheapJuly 9, 2025 | msn.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.June 13 at 1:00 AM | Altimetry (Ad)Kronos Bio Completes Merger with Concentra BiosciencesJune 20, 2025 | tipranks.comKronos Bio sends Cambridge lab space back to marketJune 5, 2025 | bizjournals.comKronos Bio Terminates Cambridge Lease AgreementJune 5, 2025 | tipranks.comOrca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial OfficerJune 4, 2025 | finance.yahoo.comKRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRONMay 4, 2025 | businesswire.comSee More Headlines KRON Stock Analysis - Frequently Asked Questions How were Kronos Bio's earnings last quarter? Kronos Bio, Inc. (NASDAQ:KRON) released its earnings results on Tuesday, March, 18th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.13. The company earned $2.27 million during the quarter, compared to analyst estimates of $1 million. Kronos Bio had a negative net margin of 701.53% and a negative trailing twelve-month return on equity of 64.22%. When did Kronos Bio IPO? Kronos Bio (KRON) raised $224 million in an initial public offering (IPO) on Friday, October 9th 2020. The company issued 13,157,895 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO. What other stocks do shareholders of Kronos Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kronos Bio investors own include Bank of America (BAC), AT&T (T), Energy Transfer (ET), ARMOUR Residential REIT (ARR), Prospect Capital (PSEC) and New Gold (NGD). Company Calendar Last Earnings3/18/2025Today6/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (15m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 KRON's financial health is in the Yellow zone, according to TradeSmith. KRON has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRON CIK1741830 Webkronosbio.com Phone650-781-5200FaxN/AEmployees100Year Founded2017Profitability EPS (Trailing Twelve Months)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$86.08 million Net Margins-701.53% Pretax Margin-701.53% Return on Equity-64.22% Return on Assets-47.17% Debt Debt-to-Equity RatioN/A Current Ratio12.93 Quick Ratio12.93 Sales & Book Value Annual Sales$9.85 million Price / Sales5.45 Cash FlowN/A Price / Cash FlowN/A Book Value$1.45 per share Price / Book0.61Miscellaneous Outstanding Shares61,050,000Free Float46,155,000Market Cap$53.72 million OptionableOptionable Beta1.64 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:KRON) was last updated on 6/13/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kronos Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kronos Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
